Johnson & Johnson’s Cordis Corporation said on Friday that Britain’s leading private health insurance group had decided to reimburse its drug-coated coronary stents.
The Cypher stent, which releases sirolimus to prevent restenosis, was introduced in April following CE market approval but is not yet widely used in Britain’s state-funded National Health Service.
Cordis said in a statement that people insured privately with BUPA, which has 2.8 million members, could now be treated with the new technology, significantly reducing the potential need for repeat hospital visits for additional angioplasty or more costly surgery.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!